74 related articles for article (PubMed ID: 18065738)
1. Detection of early-stage ovarian cancer by FDG-PET-CT in a patient with BRCA2-positive breast cancer.
Milam RA; Milam MR; Iyer RB
J Clin Oncol; 2007 Dec; 25(35):5657-8. PubMed ID: 18065738
[No Abstract] [Full Text] [Related]
2. [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].
Zhao TT; Li JG; Li YM
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):206-9. PubMed ID: 17649638
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma.
Haerle SK; Strobel K; Hany TF; Sidler D; Stoeckli SJ
Head Neck; 2010 Mar; 32(3):319-25. PubMed ID: 19626642
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
5. Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report.
Fruscalzo A; Damante G; Calcagno A; Di Loreto C; Marchesoni D
Cancer Invest; 2006 Oct; 24(6):611-4. PubMed ID: 16982466
[TBL] [Abstract][Full Text] [Related]
6. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT.
Monzawa S; Adachi S; Suzuki K; Hirokaga K; Takao S; Sakuma T; Hanioka K
Ann Nucl Med; 2009 Dec; 23(10):855-61. PubMed ID: 19876704
[TBL] [Abstract][Full Text] [Related]
9. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
10. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
[TBL] [Abstract][Full Text] [Related]
11. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
Fagotti A; Fanfani F; Rossitto C; Lorusso D; De Gaetano AM; Giordano A; Vizzielli G; Scambia G
Oncology; 2008; 75(3-4):152-8. PubMed ID: 18827492
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer therapy: the role of PET-CT in decision making.
Pons F; Duch J; Fuster D
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):210-23. PubMed ID: 19293769
[TBL] [Abstract][Full Text] [Related]
13. Incidental PET/CT findings in the cancer patient: how should they be managed?
Beatty JS; Williams HT; Aldridge BA; Hughes MP; Vasudeva VS; Gucwa AL; David GS; Lind DS; Kruse EJ; McLoughlin JM
Surgery; 2009 Aug; 146(2):274-81. PubMed ID: 19628085
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of incidental PET/CT findings suspicious for breast cancer in women with non-breast malignancies.
Beatty JS; Williams HT; Gucwa AL; Hughes MP; Vasudeva VS; Aldridge BA; Fields DM; David GS; Lind DS; Kruse EJ; McLoughlin JM
Am J Surg; 2009 Oct; 198(4):495-9. PubMed ID: 19800454
[TBL] [Abstract][Full Text] [Related]
15. FDG PET-CT in the management of primary breast lymphoma.
Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis.
Mansueto M; Grimaldi A; Mangili G; Picchio M; Giovacchini G; Viganò R; Messa C; Fazio F
Eur J Cancer Care (Engl); 2009 Nov; 18(6):612-9. PubMed ID: 19549284
[TBL] [Abstract][Full Text] [Related]
17. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer.
Hauth EA; Antoch G; Stattaus J; Kuehl H; Veit P; Bockisch A; Kimmig R; Forsting M
Eur J Radiol; 2005 Nov; 56(2):263-8. PubMed ID: 16233894
[TBL] [Abstract][Full Text] [Related]
19. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
20. Incidental PET/CT detection of thyroid and breast cancer during recurrence of colorectal carcinoma.
Nguyen BD
Clin Nucl Med; 2007 Jan; 32(1):59-63. PubMed ID: 17179811
[No Abstract] [Full Text] [Related]
[Next] [New Search]
